(DCPH) – Business Wire
-
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
-
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
-
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
-
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Canc
-
GENESIS Pharma Announces an Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize RIPRETINIB in 14 EU Markets in Central and Eastern Europe
-
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIS
-
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
-
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
-
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2
-
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
-
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer
-
Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023
-
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society
-
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
-
Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
-
Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days
-
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GI
-
Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
-
Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT
-
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results
-
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
-
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
-
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
-
Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations
-
Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
-
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
-
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
-
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
-
Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022
-
Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO)
-
Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022
-
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology
-
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results
-
Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 4, 2022
-
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer
Back to DCPH Stock Lookup
